Moreover, exosomal molecules like PD1 and PD-L1 are closely linked to immunotherapy resistance and poor prognosis in metastatic melanoma, making them effective for predicting therapeutic outcomes and enabling real-time monitoring of treatment efficacy. Here, CD274 is linked to metastatic melanoma.